Callan JMB signs support services deal with Cavalry 1838 Equine Biosciences for 60% revenue share

• Callan JMB signed a strategic support services agreement with Cavalry 1838 Equine Biosciences to support commercialization at the Atlas Complex.
• Deal gives Callan JMB a 60% participation in enterprise revenue, expanding its recurring infrastructure services business.
• Base-case plan targets annual revenue of USD 12 million to USD 25 million within seven years for the enterprise.
• Alabama operations will be based at the Atlas Complex, with Kansas set as the primary serum collection and production site.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Callan JMB Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040800PRIMZONEFULLFEED9803112) on August 04, 2026, and is solely responsible for the information contained therein.